HRMY vs REGN: which is the better buy in 2026?
Harmony Biosciences Holdings, Inc.
NASDAQ:HRMY
A cash-gushing rare disease franchise trading at 6x forward earnings while the market waits for pitolisant to escape narcolepsy.
Full HRMY analysisRegeneron Pharmaceuticals
NASDAQ:REGN
Dupixent's global dominance and a deep late-stage pipeline make REGN a rare large-cap biotech trading below its growth rate.
Full REGN analysisFactor by factor
Get head-to-heads like this, free
Join the Alexandria e-letter for Compass verdicts, earnings intelligence, and the contrarian calls the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is HRMY or REGN the better buy in 2026?
HRMY and REGN are neck and neck at 88/100 on the Compass right now. The better fit depends on which factors matter most to you.
How does Alexandria compare HRMY and REGN?
Each company is scored 1-100 on eight factors: revenue growth, profitability, valuation, momentum, theme purity, moat, catalysts, and market position. The Compass Score is the composite, and the comparison below shows where each name wins factor by factor.
Compass Scores are proprietary editorial research from publicly available data, not investment advice or a recommendation regarding any security. Rankings update weekly.